林业发展局批准Imfinzi在改善存活状况的基础上,对早期胃癌进行化疗。 FDA approves Imfinzi for early-stage gastric cancer with chemo, based on improved survival.

美国食品和药物管理局批准了AstraZeneca的Imfinzi,用于在手术前后用于化疗的早期胃癌和食道癌。 The U.S. FDA has approved AstraZeneca’s Imfinzi for early-stage gastric and gastroesophageal cancers when used with chemotherapy before and after surgery. 根据MATTERHORN的试验,这项批准表明,生存情况有所改善,疾病发病率降低。 The approval, based on the MATTERHORN trial, shows improved survival and reduced disease progression. 这是美国继早期肺癌和膀胱癌后第三次批准Imfinzi手术。 It’s the third U.S. perioperative approval for Imfinzi, following earlier uses in lung and bladder cancers. 该药物促进了对肿瘤的免疫反应,到2025年9月,销售额达到43.2亿美元。 The drug, which boosts immune response against tumors, saw $4.32 billion in sales through September 2025. 欧盟、日本、加拿大和其它区域正在进行监管审查。 Regulatory reviews are ongoing in the EU, Japan, Canada, and other regions.